Rania Bassiouni[Author] - Search Results

Year	Number of Results
2011	1
2016	1
2017	2
2021	2
2023	2
2024	0

1

Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer.

Bassiouni R, Idowu MO, Gibbs LD, Robila V, Grizzard PJ, Webb MG, Song J, Noriega A, Craig DW, Carpten JD. Bassiouni R, et al. Cancer Res. 2023 Jan 4;83(1):34-48. doi: 10.1158/0008-5472.CAN-22-2682. Cancer Res. 2023. PMID: 36283023 Free PMC article.

2

Applicability of spatial transcriptional profiling to cancer research.

Bassiouni R, Gibbs LD, Craig DW, Carpten JD, McEachron TA. Bassiouni R, et al. Mol Cell. 2021 Apr 15;81(8):1631-1639. doi: 10.1016/j.molcel.2021.03.016. Epub 2021 Apr 6. Mol Cell. 2021. PMID: 33826920 Free PMC article. Review.

3

Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.

Yang M, Shen H, Flodby P, Koss MD, Bassiouni R, Liu Y, Jashashvili T, Neely A, Ogbolu E, Castillo J, Stueve TR, Mullen DJ, Ryan AL, Carpten J, Castaldi A, Wallace WD, Zhou B, Borok Z, Marconett CN. Yang M, et al. Among authors: bassiouni r. Cell Rep. 2023 Dec 26;42(12):113286. doi: 10.1016/j.celrep.2023.113286. Epub 2023 Nov 22. Cell Rep. 2023. PMID: 37995179 Free PMC article.

4

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.

Flores O, Santra S, Kaittanis C, Bassiouni R, Khaled AS, Khaled AR, Grimm J, Perez JM. Flores O, et al. Among authors: bassiouni r. Theranostics. 2017 Jun 24;7(9):2477-2494. doi: 10.7150/thno.18879. eCollection 2017. Theranostics. 2017. PMID: 28744329 Free PMC article.

5

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.

Baldelli E, El Gazzah E, Moran JC, Hodge KA, Manojlovic Z, Bassiouni R, Carpten JD, Ludovini V, Baglivo S, Crinò L, Bianconi F, Dong T, Loffredo J, Petricoin EF, Pierobon M. Baldelli E, et al. Among authors: bassiouni r. Genes (Basel). 2021 Sep 11;12(9):1402. doi: 10.3390/genes12091402. Genes (Basel). 2021. PMID: 34573384 Free PMC article.

6

Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.

Carr AC, Khaled AS, Bassiouni R, Flores O, Nierenberg D, Bhatti H, Vishnubhotla P, Manuel JP, Santra S, Khaled AR. Carr AC, et al. Among authors: bassiouni r. Oncotarget. 2017 Nov 25;8(66):110273-110288. doi: 10.18632/oncotarget.22681. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299146 Free PMC article.

7

Two-photon fluorescence lysosomal bioimaging with a micelle-encapsulated fluorescent probe.

Andrade CD, Yanez CO, Qaddoura MA, Wang X, Arnett CL, Coombs SA, Yu J, Bassiouni R, Bondar MV, Belfield KD. Andrade CD, et al. Among authors: bassiouni r. J Fluoresc. 2011 May;21(3):1223-30. doi: 10.1007/s10895-010-0801-3. Epub 2011 Jan 18. J Fluoresc. 2011. PMID: 21243414

8

Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.

Bassiouni R, Nemec KN, Iketani A, Flores O, Showalter A, Khaled AS, Vishnubhotla P, Sprung RW Jr, Kaittanis C, Perez JM, Khaled AR. Bassiouni R, et al. Clin Cancer Res. 2016 Sep 1;22(17):4366-79. doi: 10.1158/1078-0432.CCR-15-2502. Epub 2016 Mar 24. Clin Cancer Res. 2016. PMID: 27012814 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year